BeOne Medicines Deal History & Licensing Activity
BeOne Medicines is a mid-size pharma. Over the past three years, BeOne Medicines has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
BeOne Medicines Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BeOne Medicines in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HH160 | Huahui Health | Other | Unknown | option | May 29, 2026 |
BeOne Medicines Pipeline Focus
Therapeutic areas and modalities where BeOne Medicines is most active based on deal history and clinical trial data.
Therapeutic Areas
BeOne Medicines Strategic Signals
Key indicators of BeOne Medicines's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
BeOne Medicines Clinical Pipeline
BeOne Medicines has 50 active clinical trials across 5 development phases.
1
Unknown
1
Phase 4
27
Phase 1
12
Phase 2
9
Phase 3
See How Your Asset Matches BeOne Medicines's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About BeOne Medicines Licensing & Deal Activity
BeOne Medicines is a mid-size pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, BeOne Medicines ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BeOne Medicines include Solid Tumors (17 deals and trials), Hematological Malignancies (15 deals and trials), Other (2 deals and trials), and Oncology (2 deals and trials). In terms of modality, BeOne Medicines has shown particular interest in other, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BeOne Medicines and 850+ other biopharma companies. Use our Solidus to benchmark your asset against BeOne Medicines's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.